The lecanemab group also had substantial decreases to the number of misfolded proteins inthe brain called tau tangles. These proteins increased in the control group. “Tau is the abnormal protein in Alzheimer’s disease that has the best correlation with clinical decline,” says Lea Grinberg at the University of California, San Francisco.

To read more of the news click here: https://www.newscientist.com/article/2349153-alzheimers-drug-lecanemab-slows-cognitive-decline-but-concerns-linger/